Johnson & Johnson's Dividend Growth and Operational Streamlining Drive Stock Rally
Johnson & Johnson (JNJ) has seen its stock rise over 50% in the past year due to operational streamlining and a focus on high-growth pharmaceuticals. The company, known for its 64-year dividend streak, is transitioning from a defensive play to a growth-oriented business with new drug launches and a strong MedTech segment. Analysts expect a 15% EPS decline in 2026 due to the loss of exclusivity for Stelara.
Tickers: $JNJ
Topics: dividend drug development Johnson & Johnson MedTech pharmaceuticals stock rally